Breaking News, Financial News

Financial Report: Hospira 1Q

Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira's proprietary sedation agent.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 1Q10 1Q Revenues: $1.0 billion (+17%) 1Q Earnings: $141.7 million (-14%) Comments: Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira’s proprietary sedation agent. Global Specialty Injectables revenue was $611.4 million in the quarter, up 42%. In the Americas, revenue was $483.9 million (+45%). In Europe, Middle East & Africa sales were $69.9 million (+2...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters